Dramatic response to immunotherapy in an epidermal growth factor receptor-mutant non-small cell lung cancer: A case report  

作　　者：Ding Li Cheng Cheng Wen-Ping Song Pei-Zan Ni Wen-Zhou Zhang Xuan Wu 

机构地区：[1]Department of Pharmacy,Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450008,Henan Province,China [2]Henan Engineering Research Center for Tumor Precision Medicine and Comprehensive Evaluation,Zhengzhou 450008,Henan Province,China [3]Department of Hematology,Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450008,Henan Province,China [4]Department of Radiotherapy,Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450008,Henan Province,China [5]Department of Internal Medicine,Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450008,Henan Province,China

出　　处：《World Journal of Clinical Cases》2021年第36期11419-11424,共6页世界临床病例杂志

基　　金：Henan Provincial Science and Technology Research Project,No.202102310157;Medical Science and Technology Research Plan(Joint Construction)Project of Henan Province,No.LHGJ20190676.

摘　　要：BACKGROUND The advent of immune checkpoint inhibitors(ICIs)has revolutionized the management of several types of solid cancers,including lung cancer,by boosting the body's natural tumor killing response.However,it is undeniable that only a small proportion of non-small cell lung cancer(NSCLC)patients with epidermal growth factor receptor(EGFR)mutations can achieve long-term responses and benefit from immunotherapy.CASE SUMMARY Herein,we report the case of a 48-year-old man diagnosed with stage IV lung adenocarcinoma with an EGFR L858R mutation who was administered pembrolizumab monotherapy followed by pemetrexed and achieved a 10-month progression-free survival interval.In this case report,we show that ICIs were effective for our patient with EGFR-mutated NSCLC and discuss the characteristics of patients who can benefit from immunotherapy.CONCLUSION We suggest that patients with EGFR-mutated NSCLC with high PD-L1 expression(defined as≥25%),the L858R mutation,smoking history,or pemetrexed pretreatment may benefit from immunotherapy.

关 键 词：Epidermal growth factor receptor mutation Non-small cell lung cancer PEMETREXED IMMUNOTHERAPY Case report 

分 类 号：R734.2[医药卫生—肿瘤]